Although direct clinical trials targeting HIF-1α in ADPKD are lacking, the preclinical evidence provides a compelling rationale for exploring HIF-1α inhibitors as potential therapeutic agents in this disease context. This evidence concerns the gene HIF1A and autosomal dominant polycystic kidney disease.